Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis

Published:2023-08-01 Issue:8 Volume:46 Page:1112-1119
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Masui Sho¹,Yonezawa Atsushi¹,Nakamura Miyuki¹,Onishi Akira²,Hashimoto Motomu³,Onizawa Hideo²,Fujii Takayuki⁴,Murakami Kosaku⁵,Murata Koichi⁴,Tanaka Masao²,Yokoyama Kotoko⁶,Iwamoto Noriko⁶,Shimada Takashi⁶,Itohara Kotaro¹,Hira Daiki¹,Nakagawa Shunsaku¹,Imai Satoshi¹,Nakagawa Takayuki¹,Hayakari Makoto¹,Matsuda Shuichi⁴,Morinobu Akio⁷,Terada Tomohiro¹,Matsubara Kazuo¹

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital

2. Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University

3. Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine

4. Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University

5. Center for Cancer Immunotherapy and Immunobiology, Division of Clinical Immunology and Cancer Immunotherapy, Graduate School of Medicine, Kyoto University

6. SHIMADZU Corporation

7. Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/46/8/46_b23-00192/_pdf

Reference31 articles.

1. 1) Maini R, St. Clair E, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet, 354, 1932–1939 (1999).

2. 2) Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med., 343, 1594–1602 (2000).

3. 3) Vallejo-Yagüe E, Keystone EC, Kandhasamy S, Micheroli R, Finckh A, Burden AM. Primary and secondary non-response: in need of operational definitions in observational studies. Ann. Rheum. Dis., 80, 961–964 (2021).

4. 4) Keystone EC, Rampakakis E, Movahedi M, Cesta A, Stutz M, Sampalis JS, Nantel F, Maslova K, Bombardier C. Toward defining primary and secondary nonresponse in rheumatoid arthritis patients treated with anti-TNF: results from the BioTRAC and OBRI registries. J. Rheumatol., 47, 510–517 (2020).

5. 5) Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford), 46, 1153–1156 (2007).